ZLAB241220C15000
- 0.00
- 0.000.00%
Zai Lab Newsroom
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $50
Zai Lab Analyst Ratings
Leerink Partners Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $72
Analysts' Top Healthcare Picks: Universal Health (UHS), Zai Lab (ZLAB)
[Brokerage Focus] Guotai Junan International reiterated a 'buy' rating on Zai Lab (09688), the company's global equity innovative drug pipeline is progressing smoothly.
Zaiding Pharmaceutical (09688.HK): DLL3 ADC data is positive and recent catalysts are abundant
U.S. stock market anomaly: zai lab surged 10% before the market opened and received a target price increase from jpmorgan.
Zaiding Pharmaceutical (9688.HK): Excellent initial efficacy and safety data of DLL3ADC
Zai Lab Is Maintained at Overweight by JP Morgan
Zai Lab Analyst Ratings
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $38
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Cuts Target Price to $38
Strong Buy Rating for Zai Lab: Outperforming Vyvgart Sales and Promising Global Pipeline Fuel Optimism
Zaiding Pharmaceutical (09688.HK): KARXT has been approved for marketing by the FDA and will soon be submitted by the Chinese NDA
Morgan Stanley Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $50
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
Buy Rating Affirmed for Zai Lab on Robust Drug Sales Growth and Strong Market Position
Zaiding Pharmaceutical (09688.HK): From outward to inner butterfly, global BIOPHARMA is on the rise
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Announces Target Price $25